Recent news about
Astellas Pharma Inc. has reflected a variety of developments influencing the company's prospects. The company's
capitalization of debt is considered to be well-managed, supporting its financial status while
submitting a new drug application for
Aavacincaptad Pegol for Geographic Atrophy in Japan. It has also announced a collaboration with
YASKAWA to innovate in cell therapy. The firm continues to support its commitment towards
sustainability and innovation. Yet, the
R&D sector of the company has been challenged, raising certain questions around its strategy.
Astellas stock performance is reportedly reflecting weak fundamentals.
Detainment of an Astellas employee in China has also surfaced, although specific actions prompting it are unknown. Several
licensing deals have been signed recently with AviadoBio and Sangamo Therapeutics as well as
research collaborations with Poseida Therapeutics and UMass Chan Medical School. The
FDA has approved VYLOY™ (zolbetuximab) for advanced gastric and GEJ cancer, as well as expanded the label for
IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy.
Astellas Pharma Inc. News Analytics from Wed, 31 May 2017 16:44:13 GMT to Tue, 25 Mar 2025 08:27:28 GMT -
Rating -1
- Innovation 5
- Information 7
- Rumor -2
